J.W. Cole Advisors’s Editas Medicine EDIT Stock Holding History

J.W. Cole Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-84,661	Closed	-$660K	–	826
2023 Q3	$660K	Buy	+84,661	New	+$726K	0.05%	347

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

J.W. Cole Advisors's EDIT Position: Q4 2023 in Review

J.W. Cole Advisors sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 84,661 shares — an estimated $660K sold.

J.W. Cole Advisors first reported a position in EDIT in Q3 2023 and held it in 1 quarter. The position peaked at $660K in Q3 2023. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

J.W. Cole Advisors reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
J.W. Cole Advisors sold 84,661 Editas Medicine shares in Q4 2023, an estimated $660K.
J.W. Cole Advisors first reported a position in Editas Medicine in Q3 2023 and held it in 1 quarter.
J.W. Cole Advisors's Editas Medicine position peaked at $660K in Q3 2023.
225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on J.W. Cole Advisors's 13F filing for Q4 2023, filed 31 Jan 2024.